MakeMoney_Mike

$QTEX has built a solid platform at these levels for a few sessions now and will be ready to move up sooner than a lot think. $NFLX $BLBX $TEM $AGYS $UAL $NVDA $ORCL $VST $TRV $COIN $MSTR $TSLA $STX $AVGO $ASST $NEHC $USEG $IPA $MGX $CDIO $RZLV $EONR $TEM $QUBT $PDYN $BLBX $RVSN $IVDA $HKPD $BTBT $SONN $OPEN $BBAI $SPCX

$ZLAB just secured ~$250M in a PIPE at $22.04, led by TCGX with participation from RA Capital, RTW, Wellington, Cormorant, Frazier Life Sciences and others.0 Proceeds are primarily earmarked for global development of zoci (zocilurtatug pelitecan), their DLL3-targeting ADC. This is elite institutional conviction right as the company presents first global Phase 1b/1c data for zoci + atezolizumab (± carboplatin) in 1L extensive-stage SCLC at #ESMO2026 (poster Oct 26; investor call today).30 Zoci already has FDA Fast Track (epNECs) + Orphan designations, prior encouraging signals (including intracranial activity in SCLC and ~38% ORR in pretreated epNECs), and plans for multiple registrational studies. Stock is sitting near the placement price after the typical dilution dip—strong capital + near-term catalysts + differentiated oncology asset. Bullish setup into the data and beyond. Not advice, DYOR.

$EYPT trading at a market value 3x below cash held is oversold massively. $NFLX $BLBX $TEM $AGYS $UAL $NVDA $ORCL $VST $TRV $COIN $MSTR $TSLA $STX $AVGO $ASST $NEHC $USEG $IPA $MGX $CDIO $RZLV $EONR $TEM $QUBT $PDYN $BLBX $RVSN $IVDA $HKPD $BTBT $SONN $OPEN $BBAI $SPCX

Today’s Market Movers Watchlist (Pre-Market, Oct 22 2026) Futures soft: Nasdaq ~-1.6% | S&P ~-1% | Dow ~-0.6%
Oil surging (WTI ~$99+, Brent ~$112) on Middle East tensions (US/Israel-Iran reports + Houthi activity). 🟢 Notable Gainers
$STAK ~+50–54% (results)
$BHVN ~+33–35%
$NCPL ~+30%
$BKYI ~+26%
$QS ~+7–8% (narrower Q3 loss + 100-MWh AI/data-center battery line plans)
$SPOT ~+5–6% 🔴 Notable Losers
Chips/AI under pressure (SOXX/DRAM ~-3.5–4%): $LRCX ~-8%, $NVDA, $AMD, $MU, $INTC soft
$TSLA ~-3.5–5% (post-earnings; capex/outlook concerns)
$META ~-1–3% (beat but AI spend scrutiny)
$IBM ~-6–7%
Crypto-linked names (e.g. $MSTR) weaker with BTC pullback Small-cap percentage movers dominate the extreme lists. All figures approximate & pre-market — subject to change at the open. Not advice. #MarketMovers #Stocks #PreMarket

$WQEY owns ~88.5% of $SAIQ (WISeSat.Space) on a beneficial basis. Direct holding ~23.4M shares; +SEALSQ affiliate brings total to ~26.4M. Parent (post-quantum cyber + identity) controlling its secure satellite IoT sub. Same CEO. #WQEY #SAIQ They will come for it soon enough

$ZURA setup looking strong into the coming days:34 Today’s AbbVie Phase 3 Lutikizumab (IL-1α/β) data in hidradenitis suppurativa (HS) hit statistical significance but with a weak ~8-point delta (HiSCR75: 31.4% vs 23.4% placebo). This underwhelming result for a competitor mechanism that was expected to advance first is a clear positive for Zura Bio’s differentiated approach.54 Why it can run near-term: •TibuSHIELD Phase 2 (HS) fully enrolled (247 patients, exceeded target) with topline data expected in Q4 2026 — the nearest major catalyst is approaching.44 •Tibulizumab is a first-in-class bispecific antibody targeting both IL-17A and BAFF, aiming for better efficacy than single-pathway agents in complex diseases like HS. •Solid balance sheet: ~$205M cash (as of June 30, 2026) with runway expected through at least the end of 2028.18 •Analyst consensus targets ~$17–18 (high $22) versus ~$4 current price — significant upside if data delivers.3 •Additional near-term events: TibuSURE (systemic sclerosis) data in H1 2027 and planned Phase 2 start in polymyalgia rheumatica by year-end 2026. This is a classic biotech binary with de-risked competition heading into data. Not financial advice — DYOR. #ZURA #biotech $NFLX $BLBX $TEM $AGYS $UAL $NVDA $ORCL $VST $TRV $COIN $MSTR $TSLA $STX $AVGO $ASST $NEHC $USEG $IPA $MGX $CDIO $RZLV $EONR $TEM $QUBT $PDYN $BLBX $RVSN $IVDA $HKPD $BTBT $SONN $OPEN $BBAI $SPCX

$QTEX is quietly becoming a key infrastructure play for scaled quantum computing. Its Additively Manufactured Electronics (AME) platform targets the physical interconnect bottleneck inside cryostats. Recent independent testing by a leading quantum company at 20 millikelvin showed >100 dB channel isolation (roughly 60 dB better than leading flexible cabling), with no detectable crosstalk, stable performance through cooldowns/bending, and a binding agreement being finalized.39 They’ve also unveiled an architecture supporting up to 17,280 coaxial lines per cryogenic stage (more than 4× the highest publicly disclosed benchmarks), plus early traction with a major Israeli defense company and a cleaner capital structure after warrant exercises.47 Quantum systems need denser, lower-heat-load, higher-integrity interconnects to scale. If execution and commercial deals land in the coming quarters, $QTEX has a clear path for re-rating from its current ~$100M market-cap range. Volatile small-cap with real technical catalysts — not a sure thing, but the setup is interesting. NFA / DYOR. Quantum hardware is early and capital-intensive.

Adding more $QTEX here ~$1.45-1.50. Why? Insiders just bought higher — CEO picked up shares at $1.67 and $1.49, Director at $1.50 (all open market, last couple weeks). They know the story better than anyone. Quantum interconnect tech just got independent validation at 20mK (100+ dB isolation), clean cap table, Nasdaq compliance restored, and defense/AME traction building. Analyst targets ~$5. Smart money is accumulating. Following. 🚀 #QTEX #QuantumComputing #Stocks $NFLX $BLBX $TEM $AGYS $UAL $NVDA $ORCL $VST $TRV $COIN $MSTR $TSLA $STX $AVGO $ASST $NEHC $USEG $IPA $MGX $CDIO $RZLV $EONR $TEM $QUBT $PDYN $BLBX $RVSN $IVDA $HKPD $BTBT $SONN $OPEN $BBAI $SPCX

$EYPT trading at a ~$37M market cap while holding ~$118M in cash & short-term investments (as of 9/30). That’s roughly 1/3 of cash (negative EV) after the wet AMD Phase 3 miss and 53% workforce cut. Market is pricing the remaining DME program (readout Q4 2027) at near zero. You do the math